Drug firm Zydus Cadila has received the final approval from the US health regulator for its Fluconazole tablets and Clobetasol Propionate spray.
The company has received "final approval from the United States Food and Drug Administration (USFDA) to market Fluconazole tablets USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate Spray 0.05 per cent", Cadila Healthcare said in a filing to BSE.
Fluconazole tablets are used to treat fungal infections. They will be produced at the group's manufacturing facility at Baddi, it said.
"Clobetasol Propionate spray, used in the treatment of various skin disorders will be manufactured at the group's dedicated topical plant located at Changodar, Ahmedabad," Cadila Healthcare said.
The group currently has over 105 approvals, it added.
Shares of Cadila Healthcare today closed at Rs 447.80 per scrip on BSE, up 4.27 per cent from its previous close.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.